Compare Halliburton Company (HAL) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Heron Therapeutics Inc — how do they compare? Halliburton Company trades at $33.8 (market cap $29.33B), while Heron Therapeutics Inc trades at $0.47 (market cap $91.46M). The key difference: Halliburton Company is far larger — about 320.7× Heron Therapeutics Inc's market cap, and Halliburton Company pays a 1.94% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HAL | HRTX | |
|---|---|---|
Market Cap | $29.33B | $91.46M |
Sector | Energy | Health |
52-Week High | $42.98 | $1.96 |
52-Week Low | $20.50 | $0.39 |
Enterprise Value | $35.41B | $189.36M |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $35.56, up 0.97% on the day, with a bullish technical signal supported by moving averages. The company shows solid fundamentals with a P/E of 19.46 and ROE of 14.56%, though net income declined to $1.28B in 2025. Recent contract wins with Aramco in Saudi Arabia and TotalEnergies in Suriname highlight growth opportunities, while analyst consensus is strongly bullish with a $44.78 price target.
Outlook remains positive due to strategic contracts and oil price support from geopolitical tensions, but risks include Middle East volatility and cost pressures. The stock offers value with earnings beats and institutional backing, though investors should monitor debt levels and execution on new projects.
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
